Analyst Price Targets — SEPN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 12, 2026 10:14 am | — | H.C. Wainwright | $60.00 | $47.76 | TheFly | Septerna price target raised to $60 from $40 at H.C. Wainwright |
| August 11, 2026 12:56 pm | — | Raymond James | $49.00 | $44.91 | TheFly | Septerna price target raised to $49 from $45 at Raymond James |
| August 11, 2026 11:39 am | Alex Thompson | Stifel Nicolaus | $49.00 | $42.14 | StreetInsider | Septerna Inc (SEPN) PT Raised to $49 at Stifel |
| August 11, 2026 10:47 am | — | Guggenheim | $51.00 | $38.85 | TheFly | Septerna price target raised to $51 from $45 at Guggenheim |
| July 1, 2026 10:35 am | — | Guggenheim | $45.00 | $33.49 | StreetInsider | Septerna Inc (SEPN) PT Lowered to $45 at GuggenheimMember Login |
| July 1, 2026 8:37 am | — | Truist Financial | $43.00 | $33.49 | StreetInsider | Septerna Inc (SEPN) PT Raised to $43 at Truist SecuritiesMember Login |
| June 11, 2026 10:15 am | — | Guggenheim | $52.00 | $30.47 | TheFly | Septerna initiated with a Buy at Guggenheim |
| June 8, 2026 10:32 am | — | Raymond James | $53.00 | $31.15 | TheFly | Septerna price target raised to $53 from $47 at Raymond James |
| March 10, 2026 1:24 pm | Josh Schimmer | Cantor Fitzgerald | $60.00 | $28.06 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Septerna Inc (SEPN) |
| January 20, 2026 11:19 am | — | H.C. Wainwright | $35.00 | $26.07 | TheFly | Septerna price target raised to $35 from $30 at H.C. Wainwright |
Latest News for SEPN
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September:
Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, with $26.7m Q2 collaboration revenue and a new R&D program initiated. SEP-479, an oral small molecule for hypoparathyroidism, is a differentiated asset with a pivotal Q1 2027 data readout as a key…
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading…
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.56 per share a year ago.
Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355,000. The transaction reduced direct Common Stock holdings by 93.7%, leaving 793 shares directly owned post-sale.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SEPN.
U.S. House Trading
No House trades found for SEPN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.